No randomized controlled trials or prospective human safety studies have evaluated the efficacy and safety of the Wolverine Stack
TB-500 and Thymosin Beta-4 are also prohibited by WADA/USADA under S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics), applicable at all times both in-competition and out-of-competition TB-500 / Thymosin Beta-4 Clinical Trials: The RGN-352 and RGN-259 Programs RegeneRx Biopharmaceuticals has pursued two clinical development programs for Thymosin Beta-4, providing the most substantial human clinical data available for any TB-500-related compound: RGN-352 (Injectable Thymosin Beta-4 for Cardiac Repair): Phase 1 trial (completed): A double-blind, placebo-controlled study enrolled 40 healthy volunteers across four cohorts of 10 subjects each, testing escalating dose levels of intravenous Thymosin Beta-4 administered daily over 14 days
39 Boulevard Executive Residence 2nd Floor (Shop 2-01 & 2-04) 39-41 Soi Phrom Chit, Klong Tan Nuea Wattana, Bangkok 10110 Supalai Icon Sathorn 63 S Sathon Rd Thung Maha Mek, Khet Sathon Bangkok 10120 One Origin 1017, 1017/3 Phahonyothin Rd, Phaya Thai, Bangkok 10400
Although many of the aforementioned peptides are banned for use by elite athletes due to potential performance-enhancing effects, they may still offer substantial therapeutic benefits for the general patient population when used judiciously under physician supervision
, Mou, R.T
